Patients with Metastatic Melanoma Receiving Anticancer Drugs: Changes in Overall Survival, 2010-2017.

导出原文传递

翻译打印收藏纠错

作者： Florence,Poizeau ^[1] ; Sandrine,Kerbrat ^[2] ; André,Happe ^[2] ; Caroline,Rault ^[2] ; Erwan,Drezen ^[2] ; Frédéric,Balusson ^[3] ; Philippe,Tuppin ^[4] ; Bernard,Guillot ^[5] ; Anne,Thuret ^[6] ; Lise,Boussemart ^[7] ; Monica,Dinulescu ^[8] ; Marc,Pracht ^[9] ; Thierry,Lesimple ^[9] ; Catherine,Droitcourt ^[1] ; Emmanuel,Oger ^[2] ; Alain,Dupuy ^[10]

作者单位： EA 7449 (Pharmacoepidemiology and Health Services Research) REPERES, Univ Rennes, CHU Rennes, Rennes, France; PEPS Research Consortium (Pharmacoepidemiology for Health Product Safety), Rennes, France; Department of Dermatology, CHU Rennes, Rennes, France. ^[1] EA 7449 (Pharmacoepidemiology and Health Services Research) REPERES, Univ Rennes, CHU Rennes, Rennes, France; PEPS Research Consortium (Pharmacoepidemiology for Health Product Safety), Rennes, France. ^[2] EA 7449 (Pharmacoepidemiology and Health Services Research) REPERES, Univ Rennes, CHU Rennes, Rennes, France. ^[3] Department of Public Health Research, CNAM, Paris, France. ^[4] Department of Dermatology, CHU Montpellier, France. ^[5] Noncommunicable Diseases and Trauma Division, Santé Publique France, the French Public Health Agency, Saint Maurice, France. ^[6] Department of Dermatology, CHU Rennes, Rennes, France; University of Rennes 1, CNRS, IGDR, UMR 6290, Rennes, France. ^[7] Department of Dermatology, CHU Rennes, Rennes, France. ^[8] Department of Medical Oncology, Centre Eugène Marquis, Rennes, France. ^[9] EA 7449 (Pharmacoepidemiology and Health Services Research) REPERES, Univ Rennes, CHU Rennes, Rennes, France; PEPS Research Consortium (Pharmacoepidemiology for Health Product Safety), Rennes, France; Department of Dermatology, CHU Rennes, Rennes, France. Electronic address: alain.dupuy@chu-rennes.fr. ^[10]